X

Drug Profile

JW 0201

Alternative Names: JW-0201

Latest Information Update: 19 Apr 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JW Pharmaceutical
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Type 2 diabetes mellitus

Most Recent Events

12 Jan 2023 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in South Korea (PO) (NCT05814406)
03 Jan 2023 JW Pharmaceutical initiates phase-III trial in Type 2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in South Korea (PO) (NCT05814393)
23 Mar 2022 JW Pharmaceutical completes the phase I trial (In volunteers) in South Korea (PO) (NCT05463497)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com